Literature DB >> 12795780

Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors.

R B Wang1, C L Kuo, L L Lien, E J Lien.   

Abstract

OBJECTIVE: A large number of structurally and functionally diverse compounds act as substrates or modulators of p-glycoprotein (p-gp). Some of them possess multiple drug resistance (MDR)-reversing activity, but only a small number of them have entered clinical study. In order to uncover the factors which exert a significant impact on the interaction between substrates/modulators and p-gp, we have performed structure-activity relationship (SAR) analyses, including molecular modelling, two-dimensional (2D) and three-dimensional (3D) parameter-frame-setting analysis, quantitative structure activity relationship (QSAR) analysis among substrates/modulators, as well as clinically promising MDR-reversing agents.
METHODS: The physicochemical parameters C log P, CMR and all regression equations were derived by using C log P version 4.0 and the latest CQSAR software, respectively. Molecular modelling and all other parameter calculations were performed by using HyperChem version 5.0 program, after geometry optimization and energy minimization using the AM1 semiempirical method.
RESULTS: SAR analyses indicate that MDR reversal activity is correlated with the lipophilicity (C log P), molecular weight (log Mw), longest chain (Nlc) of the molecule and the energy of the highest occupied orbital (Ehomo). In addition, the presence of a basic tertiary nitrogen atom in the structure is also an important contributor to p-gp inhibitory activity. Some separation in space is achieved for different subsets of p-gp substrates and inhibitors using Nlc, C log P and Ehomo as three independent parameters in the 3D-parameter-frame setting.
CONCLUSION: A highly effective p-gp modulator candidate should possess a log P value of 2.92 or higher, 18-atom-long or longer molecular axis, and a high Ehomo value, as well as at least one tertiary basic nitrogen atom. The results obtained may be useful in explaining drug-p-gp interactions for different compounds, including drug interactions and the development of new MDR chemosensitizers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12795780     DOI: 10.1046/j.1365-2710.2003.00487.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  42 in total

Review 1.  Structure and function of efflux pumps that confer resistance to drugs.

Authors:  M Ines Borges-Walmsley; Kenneth S McKeegan; Adrian R Walmsley
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

2.  Altered intracellular pH regulation in cells with high levels of P-glycoprotein expression.

Authors:  Gregory Young; Luis Reuss; Guillermo A Altenberg
Journal:  Int J Biochem Mol Biol       Date:  2010-06-03

3.  Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and drug-bank compounds.

Authors:  Trieu-Du Ngo; Thanh-Dao Tran; Minh-Tri Le; Khac-Minh Thai
Journal:  Mol Divers       Date:  2016-07-18       Impact factor: 2.943

Review 4.  Neurobiological applications of small molecule screening.

Authors:  Andras Bauer; Brent Stockwell
Journal:  Chem Rev       Date:  2008-05-01       Impact factor: 60.622

5.  YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway.

Authors:  Chin-Chuan Hung; Horng-Huei Liou
Journal:  Invest New Drugs       Date:  2010-07-31       Impact factor: 3.850

6.  Absorptive interactions of concurrent oral administration of (+)-catechin and puerarin in rats and the underlying mechanisms.

Authors:  Hui-fang Su; Qing Lin; Xin-yi Wang; Yao Fu; Tao Gong; Xun Sun; Zhi-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-03-14       Impact factor: 6.150

7.  Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells.

Authors:  Hisakazu Ohtani; Tomomi Ikegawa; Youko Honda; Noriko Kohyama; Satoshi Morimoto; Yukihiro Shoyama; Motoharu Juichi; Mikihiko Naito; Takashi Tsuruo; Yasufumi Sawada
Journal:  Pharm Res       Date:  2007-05-10       Impact factor: 4.200

8.  Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier.

Authors:  Bernd Dörner; Claudia Kuntner; Jens P Bankstahl; Marion Bankstahl; Johann Stanek; Thomas Wanek; Gloria Stundner; Severin Mairinger; Wolfgang Löscher; Markus Müller; Oliver Langer; Thomas Erker
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

9.  Clinical significance of ABCB1 genotyping in oncology.

Authors:  Alma Hamidovic; Kristine Hahn; Jill Kolesar
Journal:  J Oncol Pharm Pract       Date:  2009-04-28       Impact factor: 1.809

10.  Prediction of P-glycoprotein inhibitors with machine learning classification models and 3D-RISM-KH theory based solvation energy descriptors.

Authors:  Vijaya Kumar Hinge; Dipankar Roy; Andriy Kovalenko
Journal:  J Comput Aided Mol Des       Date:  2019-11-19       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.